WATERS CORP /DE/ (WAT) Financial Ratio Screen

NYSE Healthcare United States USD 40330M
FINANCIAL SCREEN PASSED*
Automated financial screen · activity assessed separately
WATERS CORP /DE/ (WAT) passes all available checks in 2 implemented financial-ratio model(s). Its activity assessment is still in progress; this is not a Shariah verdict. Its debt proxy is 29.4% against the model threshold of 30%. The supplied classification is Healthcare (Diagnostics & Research); mixed activities and revenue segments remain part of the activity assessment.

Track WAT screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

WAT financial screening at a glance

FINANCIAL SCREEN PASSED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
29.4%
Pass vs 30%
Cash ratio
11.6%
Pass vs 30%
Receivables + cash
27.9%
Pass vs 30%
Impermissible income
0.6%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria passedActivity is assessed separately
FTSE/Yasaar-styleFinancial criteria passedActivity is assessed separately
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Diagnostics & Research) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 29.4%
/ 30%
11.6%
/ 30%
27.9%
/ 30%
0.59%
/ 5%
FINANCIAL SCREEN PASSED*
FTSE 29.4%
/ 33%
11.6%
/ 33%
27.9%
/ 50%
0.59%
/ 5%
FINANCIAL SCREEN PASSED*

Financial Highlights

P/E Ratio
104.3
Forward: 24.8
EPS
$3.94
P/B Ratio
2.6
EV/EBITDA
31.2
EV: $45.3B
Revenue
$3.2B
Growth: 113.4%
Beta
1.2
Average volatility
Current Ratio
1.9

Profitability

Gross Margin 56.3%
Operating Margin 9.4%
Net Margin 3.6%
Return on Equity (ROE) 1.9%
Return on Assets (ROA) 3.6%

Cash Flow & Balance Sheet

Operating Cash Flow$653M
Free Cash Flow$540M
Total Debt$1.5B
Debt-to-Equity36.0
Current Ratio1.9
Total Assets$5.1B

Price & Trading

Last Close$410.70
50-Day MA$382.26
200-Day MA$359.18
Avg Volume928K
Beta1.2
52-Week Range
$282.77
$421.74

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-25 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About WATERS CORP /DE/ (WAT)

CEO
Dr. Udit Batra Ph.D.
Employees
16,000
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NYSE
Market Cap (listing currency)
USD 40330M
Currency
USD

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is WATERS CORP /DE/ (WAT) halal to invest in?

The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is WATERS CORP /DE/'s debt ratio?

WATERS CORP /DE/'s debt ratio is 29.4% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are WATERS CORP /DE/'s key financial metrics?

WATERS CORP /DE/ has a market capitalization of USD 40330M in its listing currency, trailing P/E ratio of 104.3, and revenue of $3.2B. The company maintains a gross margin of 56.3% and a net margin of 3.6%. Return on equity stands at 1.9%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.